Abstract:OBJECTIVE:Aplastic anemia is characterized by bone marrow failure and marked reduction of white blood cells, red blood cells and platelets in peripheral blood. Clinical studies have shown that immunosuppressive therapy greatly prolonged the long-term survival of some patients with aplastic anemia. But in severe aplastic anemia (SAA) patients whose ANC was < 0.5 x 10(9)/L, platelets were < 20 x 10(9)/L, very low bone marrow proliferation and high death rate were observed. The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA. METHODS:Fifty-four cases with SAA were treated with immunosuppressive agents mentioned above in our department from Jan. 1997 to June 2003, 31 of the cases had treated with CSA combined with ATG. There were 18 cases with SAA type I and 13 cases with SAA type II in CSA combined with ATG group, and 13 cases had very severe aplastic anemia. The other 23 cases were treated with CSA alone (CSA group), 10 of these cases had SAA-I and 13 had SAA-II, and 5 cases had very severe aplastic anemia. The responsive rate, relapse, adverse reactions and event free survival (EFS) were compared between CSA combined with ATG group and CSA group. RESULTS:The proportions of patients with different types of the disease and severity were comparable between the two groups. The responsive time of the CSA combined with ATG group and CSA group was 2.5 months and 3.5 months, respectively (P < 0.05), the responsive rate in two groups was 81% (25/31) and 52% (12/23), respectively (chi(2) = 4.962, P < 0.05). In 37 cases who were responsive to therapy, the relapse rate was 8% (2/25) and 50% (6/12) respectively (chi(C)(2) = 6.143, P < 0.05). There were no significant differences in adverse reactions to the immunosuppressive agents. All cases were followed-up for more than 1 year, and the event-free survival over one year in these two groups was 81% (25/31) and 52% (12/23), respectively. Forty-seven cases were followed-up for more than two years, and the event-free survival was 74% (20/27) and 50% (10/20), respectively (P < 0.01). Twelve cases were followed-up for over 5 years. There were no secondary tumor, myelodysplastic syndrome and other colony diseases. CONCLUSION:The immunosuppressive therapies for acquired severe aplastic anemia in childhood were effective. The effect of CSA combined with ATG was better than that of CSA alone, and the relapse rate was lower with the combined treatment. However, the long-term effect needs longer follow-up studies to evaluate.

The change of CD5~+B lymphocytes in the peripheral blood of patients with childhood aplastic anemia and its clinical significance

Relationship between CD4~+CD_(25)~(high)Foxp~3+Treg Lymphocytes and CD5~+B Lymphocytes in Peripheral Blood in Children with Severe Aplastic Anemia

Effectiveness of Immunosuppressive Therapy for Childhood Aplastic Anemia and Its Predictive Factors

Clinical analysis of immunosuppressive therapy in childhood aplastic anemia

Therapeutic effects of a combination of high-dose immunoglobulin and cyclosporine A in children with aplastic anemia

A study on T - cell subgroup in peripheral blood of children with aplastic anemia

The abnormal expression of regulatory factors GAS5 and mTOR signaling pathway molecules in T cells in childhood severe aplastic anemia

[Immunosuppressive therapy for 54 children patients with acquired severe aplastic anemia].

Evaluation on the therapeutic efficacy of the combined immunosuppression therapy in children with aplastic anemia

Changes and Clinical Significance of CD8+T Cell Subset in Patients with Aplastic Anemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia

Reduced Regulatory Effects of Bone Marrow-Derived Mesenchymal Stem Cells on Activated T Lymphocytes and Th1/Th2 Cytokine Secretion in Children with Aplastic Anemia.

Analysis of lymphocyte immune abnormality in 52 cases of children idiopathic aplastic anemia]

Clinical significance of detection of T-cell subgroups in patients with aplastic anemia]

Natural history of moderate aplastic anemia in children and effects of immunosuppresstve therapy

Changes and Clinical Significances of CD4~+T Cell Subsets in Aplastic Anemia, Myelodysplastic Syndromes and Acute Myeloid Leukemia Patients

Research of Regulative Factors on CD8+ HLA-DR+ Effector T Cells in Severe Aplastic Anemia

Effects of Immunological Factors on Pathogenesis of Aplastic Anemia and Its Clinical Significane

Analysis of Peripheral T-Lymphocytic Cell Phenotypes in Children with Aplastic Anemia

Treatment of aplastic anemia with intensive immunosuppressive agents in children

Abnormal Quantity and Function of Regulatory T Cells in Peripheral Blood of Patients with Severe Aplastic Anemia

Influential factors of response to childhood aplastic anemia treated with antithymocyte globulin and Cyclosporin A